[go: up one dir, main page]

CL2019001143A1 - Dímeros de insulina, agonistas parciales del receptor de insulina (divisional solicitud 201701288) - Google Patents

Dímeros de insulina, agonistas parciales del receptor de insulina (divisional solicitud 201701288)

Info

Publication number
CL2019001143A1
CL2019001143A1 CL2019001143A CL2019001143A CL2019001143A1 CL 2019001143 A1 CL2019001143 A1 CL 2019001143A1 CL 2019001143 A CL2019001143 A CL 2019001143A CL 2019001143 A CL2019001143 A CL 2019001143A CL 2019001143 A1 CL2019001143 A1 CL 2019001143A1
Authority
CL
Chile
Prior art keywords
insulin
receptor agonists
divisional application
partial
dimers
Prior art date
Application number
CL2019001143A
Other languages
English (en)
Inventor
Songnian Lin
Lin Yan
Pei Huo
Smitri Pissarnitski
Danqing Feng
Ravi Nargund
Yuping Zhu
Ahmet Kekec
Christina B Madsen-Duggan
Zhi-Cai Shi
Zhicai Wu
Yingjun Mu
Original Assignee
Merck Sharp & Dohme
Priority date (The priority date is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the date listed.)
Filing date
Publication date
Application filed by Merck Sharp & Dohme filed Critical Merck Sharp & Dohme
Publication of CL2019001143A1 publication Critical patent/CL2019001143A1/es

Links

Classifications

    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K47/00—Medicinal preparations characterised by the non-active ingredients used, e.g. carriers or inert additives; Targeting or modifying agents chemically bound to the active ingredient
    • A61K47/50—Medicinal preparations characterised by the non-active ingredients used, e.g. carriers or inert additives; Targeting or modifying agents chemically bound to the active ingredient the non-active ingredient being chemically bound to the active ingredient, e.g. polymer-drug conjugates
    • A61K47/51—Medicinal preparations characterised by the non-active ingredients used, e.g. carriers or inert additives; Targeting or modifying agents chemically bound to the active ingredient the non-active ingredient being chemically bound to the active ingredient, e.g. polymer-drug conjugates the non-active ingredient being a modifying agent
    • A61K47/54—Medicinal preparations characterised by the non-active ingredients used, e.g. carriers or inert additives; Targeting or modifying agents chemically bound to the active ingredient the non-active ingredient being chemically bound to the active ingredient, e.g. polymer-drug conjugates the non-active ingredient being a modifying agent the modifying agent being an organic compound
    • A61K47/55—Medicinal preparations characterised by the non-active ingredients used, e.g. carriers or inert additives; Targeting or modifying agents chemically bound to the active ingredient the non-active ingredient being chemically bound to the active ingredient, e.g. polymer-drug conjugates the non-active ingredient being a modifying agent the modifying agent being an organic compound the modifying agent being also a pharmacologically or therapeutically active agent, i.e. the entire conjugate being a codrug, i.e. a dimer, oligomer or polymer of pharmacologically or therapeutically active compounds
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07K—PEPTIDES
    • C07K14/00—Peptides having more than 20 amino acids; Gastrins; Somatostatins; Melanotropins; Derivatives thereof
    • C07K14/435—Peptides having more than 20 amino acids; Gastrins; Somatostatins; Melanotropins; Derivatives thereof from animals; from humans
    • C07K14/575—Hormones
    • C07K14/62—Insulins
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K38/00—Medicinal preparations containing peptides
    • A61K38/16—Peptides having more than 20 amino acids; Gastrins; Somatostatins; Melanotropins; Derivatives thereof
    • A61K38/17—Peptides having more than 20 amino acids; Gastrins; Somatostatins; Melanotropins; Derivatives thereof from animals; from humans
    • A61K38/22—Hormones
    • A61K38/28—Insulins
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K47/00—Medicinal preparations characterised by the non-active ingredients used, e.g. carriers or inert additives; Targeting or modifying agents chemically bound to the active ingredient
    • A61K47/50—Medicinal preparations characterised by the non-active ingredients used, e.g. carriers or inert additives; Targeting or modifying agents chemically bound to the active ingredient the non-active ingredient being chemically bound to the active ingredient, e.g. polymer-drug conjugates
    • A61K47/51—Medicinal preparations characterised by the non-active ingredients used, e.g. carriers or inert additives; Targeting or modifying agents chemically bound to the active ingredient the non-active ingredient being chemically bound to the active ingredient, e.g. polymer-drug conjugates the non-active ingredient being a modifying agent
    • A61K47/56—Medicinal preparations characterised by the non-active ingredients used, e.g. carriers or inert additives; Targeting or modifying agents chemically bound to the active ingredient the non-active ingredient being chemically bound to the active ingredient, e.g. polymer-drug conjugates the non-active ingredient being a modifying agent the modifying agent being an organic macromolecular compound, e.g. an oligomeric, polymeric or dendrimeric molecule
    • A61K47/59—Medicinal preparations characterised by the non-active ingredients used, e.g. carriers or inert additives; Targeting or modifying agents chemically bound to the active ingredient the non-active ingredient being chemically bound to the active ingredient, e.g. polymer-drug conjugates the non-active ingredient being a modifying agent the modifying agent being an organic macromolecular compound, e.g. an oligomeric, polymeric or dendrimeric molecule obtained otherwise than by reactions only involving carbon-to-carbon unsaturated bonds, e.g. polyureas or polyurethanes
    • A61K47/60—Medicinal preparations characterised by the non-active ingredients used, e.g. carriers or inert additives; Targeting or modifying agents chemically bound to the active ingredient the non-active ingredient being chemically bound to the active ingredient, e.g. polymer-drug conjugates the non-active ingredient being a modifying agent the modifying agent being an organic macromolecular compound, e.g. an oligomeric, polymeric or dendrimeric molecule obtained otherwise than by reactions only involving carbon-to-carbon unsaturated bonds, e.g. polyureas or polyurethanes the organic macromolecular compound being a polyoxyalkylene oligomer, polymer or dendrimer, e.g. PEG, PPG, PEO or polyglycerol
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P3/00—Drugs for disorders of the metabolism
    • A61P3/08—Drugs for disorders of the metabolism for glucose homeostasis
    • A61P3/10—Drugs for disorders of the metabolism for glucose homeostasis for hyperglycaemia, e.g. antidiabetics
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P43/00—Drugs for specific purposes, not provided for in groups A61P1/00-A61P41/00
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K38/00—Medicinal preparations containing peptides
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07K—PEPTIDES
    • C07K2319/00—Fusion polypeptide

Landscapes

  • Health & Medical Sciences (AREA)
  • Life Sciences & Earth Sciences (AREA)
  • Chemical & Material Sciences (AREA)
  • Medicinal Chemistry (AREA)
  • General Health & Medical Sciences (AREA)
  • Engineering & Computer Science (AREA)
  • Bioinformatics & Cheminformatics (AREA)
  • Public Health (AREA)
  • Veterinary Medicine (AREA)
  • Pharmacology & Pharmacy (AREA)
  • Animal Behavior & Ethology (AREA)
  • Epidemiology (AREA)
  • Diabetes (AREA)
  • Organic Chemistry (AREA)
  • Endocrinology (AREA)
  • Gastroenterology & Hepatology (AREA)
  • Proteomics, Peptides & Aminoacids (AREA)
  • Zoology (AREA)
  • Biochemistry (AREA)
  • Biophysics (AREA)
  • Toxicology (AREA)
  • Molecular Biology (AREA)
  • Genetics & Genomics (AREA)
  • Immunology (AREA)
  • Chemical Kinetics & Catalysis (AREA)
  • General Chemical & Material Sciences (AREA)
  • Nuclear Medicine, Radiotherapy & Molecular Imaging (AREA)
  • Emergency Medicine (AREA)
  • Obesity (AREA)
  • Hematology (AREA)
  • Medicines That Contain Protein Lipid Enzymes And Other Medicines (AREA)
  • Peptides Or Proteins (AREA)
  • Medicinal Preparation (AREA)

Abstract

EL INVENTO SE RELACIONA CON DÍMEROS DE INSULINA O ANÁLOGOS DE INSULINA UNIDOS POR UN ENLAZANTE, QUE TIENEN ACTIVIDAD DE AGONISTAS PARCIALES DEL RECEPTOR DE INSULINA Y QUE INDUCEN MENOS RIESGOS DE PRODUCIR HIPOGLICEMIA, TAMBIÉN SE RELACIONA CON COMPOSICIONES QUE COMPRENDEN LOS DÍMEROS Y USOS DE LOS DÍMEROS PARA LA PREPARACIÓN DE UN MEDICAMENTO EN EL TRATAMIENTO DE LA DIABETES.
CL2019001143A 2014-11-21 2019-04-26 Dímeros de insulina, agonistas parciales del receptor de insulina (divisional solicitud 201701288) CL2019001143A1 (es)

Applications Claiming Priority (2)

Application Number Priority Date Filing Date Title
US201462082857P 2014-11-21 2014-11-21
US201562242503P 2015-10-16 2015-10-16

Publications (1)

Publication Number Publication Date
CL2019001143A1 true CL2019001143A1 (es) 2019-07-19

Family

ID=54838417

Family Applications (3)

Application Number Title Priority Date Filing Date
CL2017001288A CL2017001288A1 (es) 2014-11-21 2017-05-18 Agonistas parciales del receptor de insulina
CL2019001144A CL2019001144A1 (es) 2014-11-21 2019-04-26 Dímeros de insulina, agonistas parciales del receptor de insulina (divisional solicitud 201701288)
CL2019001143A CL2019001143A1 (es) 2014-11-21 2019-04-26 Dímeros de insulina, agonistas parciales del receptor de insulina (divisional solicitud 201701288)

Family Applications Before (2)

Application Number Title Priority Date Filing Date
CL2017001288A CL2017001288A1 (es) 2014-11-21 2017-05-18 Agonistas parciales del receptor de insulina
CL2019001144A CL2019001144A1 (es) 2014-11-21 2019-04-26 Dímeros de insulina, agonistas parciales del receptor de insulina (divisional solicitud 201701288)

Country Status (26)

Country Link
US (4) US20170355743A1 (es)
EP (4) EP3660041B1 (es)
JP (5) JP6484337B2 (es)
KR (2) KR102101136B1 (es)
CN (2) CN108064173B (es)
AR (1) AR102712A1 (es)
AU (3) AU2015349890B2 (es)
CA (2) CA3014641C (es)
CL (3) CL2017001288A1 (es)
CO (1) CO2017004976A2 (es)
CR (1) CR20170208A (es)
DO (1) DOP2017000124A (es)
EA (1) EA036714B1 (es)
ES (2) ES2946247T3 (es)
GT (1) GT201700104A (es)
IL (1) IL252257A0 (es)
MX (3) MX2017006651A (es)
NI (1) NI201700060A (es)
PE (1) PE20170957A1 (es)
PH (1) PH12017500935A1 (es)
SG (4) SG10201809457YA (es)
SV (1) SV2017005445A (es)
TN (1) TN2017000178A1 (es)
TW (1) TW201625673A (es)
WO (1) WO2016081670A2 (es)
ZA (1) ZA201703238B (es)

Families Citing this family (31)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
CA2957046C (en) 2014-08-04 2022-11-15 Nuevolution A/S Optionally fused heterocyclyl-substituted derivatives of pyrimidine useful for the treatment of inflammatory, metabolic, oncologic and autoimmune diseases
EP3660041B1 (en) * 2014-11-21 2023-04-19 Merck Sharp & Dohme LLC Insulin receptor partial agonists
AR105616A1 (es) 2015-05-07 2017-10-25 Lilly Co Eli Proteínas de fusión
US10953076B2 (en) 2016-05-24 2021-03-23 Merck Sharp & Dohme Corp. Insulin receptor partial agonists and GLP-1 analogues
EP3463413A4 (en) * 2016-05-25 2020-03-04 Merck Sharp & Dohme Corp. INSULIN RECEPTOR PART AGONISTS
EP3529615A1 (en) * 2016-10-24 2019-08-28 Novo Nordisk A/S Bioassay for insulin formulations
JP2020531451A (ja) 2017-08-17 2020-11-05 ノヴォ ノルディスク アー／エス 新規のアシル化インスリン類似体およびそれらの使用
WO2020028864A1 (en) 2018-08-02 2020-02-06 Dyne Therapeutics, Inc. Muscle targeting complexes and uses thereof for treating facioscapulohumeral muscular dystrophy
US11911484B2 (en) 2018-08-02 2024-02-27 Dyne Therapeutics, Inc. Muscle targeting complexes and uses thereof for treating myotonic dystrophy
US12018087B2 (en) 2018-08-02 2024-06-25 Dyne Therapeutics, Inc. Muscle-targeting complexes comprising an anti-transferrin receptor antibody linked to an oligonucleotide and methods of delivering oligonucleotide to a subject
US11168141B2 (en) 2018-08-02 2021-11-09 Dyne Therapeutics, Inc. Muscle targeting complexes and uses thereof for treating dystrophinopathies
US12097263B2 (en) 2018-08-02 2024-09-24 Dyne Therapeutics, Inc. Muscle targeting complexes and uses thereof for treating myotonic dystrophy
US20210308273A1 (en) 2018-08-02 2021-10-07 Dyne Therapeutics, Inc. Muscle targeting complexes and uses thereof for treating dystrophinopathies
US12370264B1 (en) 2018-08-02 2025-07-29 Dyne Therapeutics, Inc. Complexes comprising an anti-transferrin receptor antibody linked to an oligonucleotide and method of delivering oligonucleotide to a subject
CN112898172B (zh) * 2019-12-04 2022-05-31 中国科学院大连化学物理研究所 可被羧肽酶酶解的双亲和功能团化合物的合成方法
WO2021124277A1 (en) 2019-12-20 2021-06-24 Nuevolution A/S Compounds active towards nuclear receptors
US11685727B2 (en) 2019-12-20 2023-06-27 Nuevolution A/S Compounds active towards nuclear receptors
EP4126874A1 (en) 2020-03-31 2023-02-08 Nuevolution A/S Compounds active towards nuclear receptors
AU2021249530A1 (en) 2020-03-31 2022-12-01 Nuevolution A/S Compounds active towards nuclear receptors
WO2022046747A1 (en) * 2020-08-26 2022-03-03 Merck Sharp & Dohme Corp. Insulin receptor partial agonists
US20230310551A1 (en) * 2020-08-26 2023-10-05 Merck Sharp & Dohme Llc Insulin receptor partial agonists
CN116457015A (zh) * 2020-09-03 2023-07-18 达因疗法公司 制备蛋白质-寡核苷酸复合物的方法
WO2022051665A1 (en) * 2020-09-03 2022-03-10 Dyne Therapeutics, Inc. Methods of preparing protein-oligonucleotide complexes
US20240294596A1 (en) * 2020-09-09 2024-09-05 Merck Sharp & Dohme Llc Insulin receptor partial agonists
US11969475B2 (en) 2021-07-09 2024-04-30 Dyne Therapeutics, Inc. Muscle targeting complexes and uses thereof for treating facioscapulohumeral muscular dystrophy
US11771776B2 (en) 2021-07-09 2023-10-03 Dyne Therapeutics, Inc. Muscle targeting complexes and uses thereof for treating dystrophinopathies
WO2023283623A1 (en) 2021-07-09 2023-01-12 Dyne Therapeutics, Inc. Muscle targeting complexes and formulations for treating dystrophinopathies
US11633498B2 (en) 2021-07-09 2023-04-25 Dyne Therapeutics, Inc. Muscle targeting complexes and uses thereof for treating myotonic dystrophy
US11638761B2 (en) 2021-07-09 2023-05-02 Dyne Therapeutics, Inc. Muscle targeting complexes and uses thereof for treating Facioscapulohumeral muscular dystrophy
US11648318B2 (en) 2021-07-09 2023-05-16 Dyne Therapeutics, Inc. Anti-transferrin receptor (TFR) antibody and uses thereof
IL316143A (en) 2022-04-15 2024-12-01 Dyne Therapeutics Inc Muscle targeting complexes and formulations for the treatment of myotonic dystrophy

Family Cites Families (42)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
GB1381273A (en) * 1971-01-28 1975-01-22 Nat Res Dev Insulin derivatives
US3907763A (en) 1972-03-01 1975-09-23 Bayer Ag Insulin derivatives crosslinked by a dicarboxylic acid moiety
PH25772A (en) 1985-08-30 1991-10-18 Novo Industri As Insulin analogues, process for their preparation
US5514646A (en) 1989-02-09 1996-05-07 Chance; Ronald E. Insulin analogs modified at position 29 of the B chain
US5304473A (en) 1991-06-11 1994-04-19 Eli Lilly And Company A-C-B proinsulin, method of manufacturing and using same, and intermediates in insulin production
AU1272295A (en) 1993-12-17 1995-07-03 Novo Nordisk A/S Proinsulin-like compounds
WO1996034882A1 (en) 1995-05-05 1996-11-07 Eli Lilly And Company Single chain insulin with high bioactivity
WO1999064045A1 (en) 1998-06-08 1999-12-16 Advanced Medicine, Inc. Novel therapeutic agents for membrane transporters
DE19908041A1 (de) * 1999-02-24 2000-08-31 Hoecker Hartwig Kovalent verbrückte Insulindimere
KR100449454B1 (ko) 2000-10-02 2004-09-21 이현철 단일사슬 인슐린 유도체의 유전자를 포함하는 당뇨병치료용 벡터
US6852694B2 (en) 2001-02-21 2005-02-08 Medtronic Minimed, Inc. Stabilized insulin formulations
US7105314B2 (en) 2001-04-02 2006-09-12 Novo Nordisk A/S Method for making human insulin precursors
KR101048279B1 (ko) 2002-05-30 2011-07-13 더 스크립스 리서치 인스티튜트 구리 촉매 작용하에서의 아지드와 아세틸렌과의 리게이션
KR100507796B1 (ko) 2003-04-03 2005-08-17 한미약품 주식회사 생체내 반감기가 증가된 ｐｅｇ-생리활성 폴리펩티드 동종이량체 결합체 및 이의 제조방법
CN1902226A (zh) 2003-12-03 2007-01-24 诺和诺德公司 单链胰岛素
EP1807105A2 (en) 2004-10-27 2007-07-18 Novo Nordisk A/S Insulin receptor binding peptides with non-insulin gene activation profiles and uses thereof
WO2006050262A2 (en) 2004-11-01 2006-05-11 The Regents Of The University Of California Compositions and methods for modification of biomolecules
JP2008533100A (ja) 2005-03-18 2008-08-21 ノボ ノルディスク アクティーゼルスカブ Ｐｅｇ化された単鎖インスリン
WO2007096332A1 (en) 2006-02-21 2007-08-30 Novo Nordisk A/S Single-chain insulin analogues and pharmaceutical formulations thereof
US20090099065A1 (en) 2006-03-13 2009-04-16 Novo Nordisk A/S Acylated Single Chain Insulin
WO2007104736A2 (en) 2006-03-13 2007-09-20 Novo Nordisk A/S Acylated single chain insulin
WO2007104734A1 (en) 2006-03-13 2007-09-20 Novo Nordisk A/S Acylated single chain insulin
EP1996223A1 (en) 2006-03-13 2008-12-03 Novo Nordisk A/S Acylated single chain insulin
US9505823B2 (en) 2006-08-07 2016-11-29 TEV A Biopharmaceuticals USA, Inc. Albumin-insulin fusion proteins
WO2008145721A2 (en) * 2007-06-01 2008-12-04 Novo Nordisk A/S N-terminal modification of polypeptides for protection against degradation by aminopeptidases
CN101983066B (zh) 2008-01-30 2016-06-29 印第安那大学科技研究公司 基于酯的胰岛素前药
KR20110021758A (ko) 2008-04-22 2011-03-04 케이스 웨스턴 리저브 유니버시티 이형체-특이적 인슐린 유사체
TWI394580B (zh) 2008-04-28 2013-05-01 Halozyme Inc 超快起作用胰島素組成物
CN103736082A (zh) * 2008-10-17 2014-04-23 赛诺菲-安万特德国有限公司 胰岛素和glp-1激动剂的组合
CA2744558A1 (en) 2008-12-19 2010-07-15 Indiana University Research And Technology Corporation Amide-based insulin prodrugs
EP2376520B1 (en) 2008-12-19 2014-02-12 Indiana University Research&Technology Corporation Insulin analogs
WO2011059895A1 (en) 2009-11-11 2011-05-19 Quest Diagnostics Investments Incorporated Hexa mutations
EP2582719B1 (en) 2010-06-16 2016-08-10 Indiana University Research and Technology Corporation Single chain insulin agonists exhibiting high activity at the insulin receptor
US8255297B2 (en) 2010-07-20 2012-08-28 Facebook, Inc. Creation, redemption, and accounting in a virtual currency system
EP2627670A2 (en) * 2010-10-15 2013-08-21 Novo Nordisk A/S Novel n-terminally modified insulin derivatives
EP2771026A4 (en) * 2011-10-27 2015-08-05 Univ Case Western Reserve ULTRA-CONCENTRATED AND FAST-ACTING INSULIN ANALOG FORMULATIONS
WO2014052451A2 (en) 2012-09-26 2014-04-03 Indiana University Research And Technology Corporation Insulin analog dimers
CA2904198A1 (en) 2013-03-15 2014-09-18 Universite De Geneve Use of insulin signaling antagonists, optionally in combination of transfection of non-beta cells, for inducing insulin production
WO2015051052A2 (en) * 2013-10-04 2015-04-09 Merck Sharp & Dohme Corp. Glucose-responsive insulin conjugates
EP3068443B1 (en) * 2013-11-12 2019-04-10 Centre for Probe Development and Commercialization Residualizing linkers and uses thereof
CR20160376A (es) 2014-01-20 2016-10-07 Hanmi Pharm Ind Co Ltd Insulina de acción prolongada y uso de la misma
EP3660041B1 (en) * 2014-11-21 2023-04-19 Merck Sharp & Dohme LLC Insulin receptor partial agonists

Also Published As

Publication number Publication date
KR102101136B1 (ko) 2020-04-14
IL252257A0 (en) 2017-07-31
EP3660041A1 (en) 2020-06-03
CA2966765A1 (en) 2016-05-26
AU2018211207A1 (en) 2018-08-16
US20170355743A1 (en) 2017-12-14
JP2019014735A (ja) 2019-01-31
WO2016081670A2 (en) 2016-05-26
AU2015349890A1 (en) 2017-06-01
KR20190069622A (ko) 2019-06-19
EP3660040B1 (en) 2025-06-18
SG10201809428UA (en) 2018-11-29
JP2020097572A (ja) 2020-06-25
AU2018211208B2 (en) 2020-09-10
EP3666792A3 (en) 2020-07-29
JP6484337B2 (ja) 2019-03-13
JP2019014734A (ja) 2019-01-31
EP3660041B1 (en) 2023-04-19
CN112494656A (zh) 2021-03-16
TN2017000178A1 (en) 2018-10-19
JP6931033B2 (ja) 2021-09-01
CA3014641A1 (en) 2016-05-26
US20180291078A1 (en) 2018-10-11
EA036714B1 (ru) 2020-12-10
JP2018501203A (ja) 2018-01-18
WO2016081670A3 (en) 2016-08-04
ZA201703238B (en) 2018-05-30
KR102049647B1 (ko) 2019-11-29
AU2018211208A1 (en) 2018-08-16
NI201700060A (es) 2017-07-18
SG10201809427SA (en) 2018-11-29
JP6943825B2 (ja) 2021-10-06
EP3221343A2 (en) 2017-09-27
GT201700104A (es) 2018-11-27
EP3666792B1 (en) 2024-12-18
ES3004386T3 (en) 2025-03-12
MX2017006651A (es) 2017-08-21
CN112494656B (zh) 2024-01-30
US10183981B2 (en) 2019-01-22
EP3660040A2 (en) 2020-06-03
ES2946247T3 (es) 2023-07-14
CL2019001144A1 (es) 2019-07-19
CL2017001288A1 (es) 2017-12-15
BR122024000898A2 (pt) 2024-02-27
SG11201704064TA (en) 2017-06-29
EP3660040A3 (en) 2020-07-29
MX2020014120A (es) 2021-03-25
SV2017005445A (es) 2018-04-04
PE20170957A1 (es) 2017-07-13
BR112017010481A8 (pt) 2023-04-11
DOP2017000124A (es) 2017-08-15
JP2019011357A (ja) 2019-01-24
AU2018211207B2 (en) 2020-04-09
JP6703068B2 (ja) 2020-06-03
CN108064173A (zh) 2018-05-22
CA3014641C (en) 2020-08-18
BR112017010481A2 (pt) 2018-04-03
BR122024000903A2 (pt) 2024-02-27
US20170107268A1 (en) 2017-04-20
KR20170084300A (ko) 2017-07-19
CR20170208A (es) 2017-07-17
US10800827B2 (en) 2020-10-13
PH12017500935A1 (en) 2017-11-27
CO2017004976A2 (es) 2017-10-10
AR102712A1 (es) 2017-03-22
EP3666792A2 (en) 2020-06-17
SG10201809457YA (en) 2018-11-29
US20190092833A1 (en) 2019-03-28
TW201625673A (zh) 2016-07-16
EA201791117A1 (ru) 2017-11-30
AU2015349890B2 (en) 2018-08-30
CA2966765C (en) 2020-04-14
CN108064173B (zh) 2021-05-18
MX2020014121A (es) 2021-03-25
EP3221343B1 (en) 2020-09-16
US10017556B2 (en) 2018-07-10

Similar Documents

Publication Publication Date Title
CL2019001143A1 (es) Dímeros de insulina, agonistas parciales del receptor de insulina (divisional solicitud 201701288)
CR20170129A (es) Uso de un agonista dual del receptor de glp-1/glucagón de acción prolongada para el tratamiento de la enfermedad del hígado graso no alcohólico
PH12016501966A1 (en) Compounds and compositions as toll-like receptor 7 agonists
NZ724878A (en) Compounds and compositions as toll-like receptor 7 agonists
CL2021002637A1 (es) Anticuerpos y fragmentos de los mismos que se unen al receptor cannabinoide 1 (cb1) humano y métodos para antagonizar cb1 (divisional de la solicitud no. 201602433)
MX2015000990A (es) Analogos del glucagon.
CL2016003075A1 (es) Composición para tratar diabetes, que contiene un conjugado de análogo de insulina de acción prolongada y un conjugado de péptido insulinotrópico de acción prolongada
GT201600147A (es) Compuestos derivados y composiciones de n-azaspirocicloalcano n-heteroaril sustituido para inhibir la actividad de shp2
MX2017014375A (es) Moduladores del ccr2.
PE20151178A1 (es) Analogos de glucagon
UY35548A (es) Péptidos terapéuticos para el tratamiento de trastornos metabólicos.
AR099569A1 (es) Derivados de insulina y los usos médicos de estos
DOP2016000226A (es) Compuestos de isoindolinona como moduladores de gpr119 para el tratamiento de diabetes, obesidad, dislipidemia y trastornos relacionados
NI201300070A (es) Ureas asimétricas y usos médicos de las mismas
DOP2016000212A (es) Heterociclos condensados sustituidos como moduladores de gpr119 para el tratamiento de la diabetes, obesidad, dislipidemia y trastornos relacionados
CL2015001538A1 (es) Compuestos derivados de piridin-2-amidas, agonistas cb2; proceso de preparacion; composicion farmaceutica que los contiene; su uso para el tratamiento o profilaxis del dolor, aterosclerosis, retinopatia diabetica, glaucoma, diabetes mellitus, entre otras.
UY35993A (es) Prolinas / piperidinas sustituidas como antagonistas del receptor de orexina
MX2016010328A (es) Tratamiento con halogeno de ataque cardiaco y lesion isquemica.
CL2015000818A1 (es) Compuestos derivados de n-prop-2-inil carboxamida, antagonistas del receptor transitorio potencial de la subfamilia 1, miembro 1 (trpa1); composicion farmaceutica que los comprende; y metodo para el tratamiento del dolor neuropatico, dolor por polineuropatia diabetica, dolor postoperatorio y dolor por cancer, entre otros.
MX2017009849A (es) Composiciones de profármaco de monometilfumarato.
DOP2016000161A (es) Ureas asimétricas p- sustituidas y usos médicos de las mismas.
MX2019014086A (es) Compuesto de insulina acilada.
CL2016000677A1 (es) Compuestos derivados de etinilo, moduladores alostericos positivos del receptor mglur4; composicion farmaceutica que los comprende; y su uso en enfermedades del snc, cancer y diabetes tipo 2.
AR093327A1 (es) Analogos quimericos de somatostatina-dopamina
ITUB20169928A1 (it) Formulazioni farmaceutiche per il trattamento del diabete